4//SEC Filing
Blackwell Kimberly 4
Accession 0001725160-22-000100
CIK 0001725160other
Filed
May 19, 8:00 PM ET
Accepted
May 20, 4:27 PM ET
Size
7.8 KB
Accession
0001725160-22-000100
Insider Transaction Report
Form 4
Blackwell Kimberly
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-05-16+1,708,809→ 1,708,809 totalExercise: $24.41Exp: 2032-05-15→ Common Stock (1,708,809 underlying) - Award
Stock Option (Right to Buy)
2022-05-16+427,202→ 427,202 totalExercise: $24.41Exp: 2032-05-15→ Common Stock (427,202 underlying)
Footnotes (2)
- [F1]The option vests and becomes exercisable as to 25% of the shares on May 16, 2023 and vests in equal monthly installments thereafter until May 16, 2026.
- [F2]The option vests and becomes exercisable as to 100% of the shares on the earlier of (a) FDA approval of a Zentalis product or (b) a Change in Control (as defined in the Issuer's 2020 Incentive Award Plan).
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001816465
Filing Metadata
- Form type
- 4
- Filed
- May 19, 8:00 PM ET
- Accepted
- May 20, 4:27 PM ET
- Size
- 7.8 KB